| Active substance |
Empagliflozin |
| Also known as |
Empa |
| Blood pressure |
Can cause a modest reduction in blood pressure |
| Chemical name |
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Dosage (medical) |
Typically 10 mg once daily, may be increased to 25 mg based on patient's condition and response |
| Dosage (sports) |
Not applicable as it is not used for enhancing athletic performance |
| Effects |
Lowers blood sugar levels, aids in weight loss, and reduces blood pressure and cardiovascular risks |
| Formula |
C23H27ClO7 |
| Half-life |
Approximately 12.4 hours |
| Hepatotoxicity |
Low risk |
| Lab Test |
Monitoring of renal function and blood glucose levels |
| Main action |
Reduces blood glucose by inhibiting glucose reabsorption in the kidney |
| Side effects |
Urinary tract infections, genital infections, increased urination, dehydration, hypotension |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
25mg |
| Substance class |
Sodium-glucose co-transporter 2 (SGLT2) inhibitor |
| Trade name |
Jardiance |
| Use in sports |
Not typically used in sports due to its mechanism focused on lowering blood glucose levels |
| Water Retention |
Can lead to a reduction in overall body water content |
| Manufacturer |
Boehringer Ingelheim Pvt. Ltd. |
| Packing |
10 tabs/blister |
